ECSP20035588A - Derivado de amino-metil piperidina como inhibidor de quinasa - Google Patents
Derivado de amino-metil piperidina como inhibidor de quinasaInfo
- Publication number
- ECSP20035588A ECSP20035588A ECSENADI202035588A ECDI202035588A ECSP20035588A EC SP20035588 A ECSP20035588 A EC SP20035588A EC SENADI202035588 A ECSENADI202035588 A EC SENADI202035588A EC DI202035588 A ECDI202035588 A EC DI202035588A EC SP20035588 A ECSP20035588 A EC SP20035588A
- Authority
- EC
- Ecuador
- Prior art keywords
- derivative
- amino
- kinase inhibitor
- methyl piperidine
- present
- Prior art date
Links
- KJWNKJWHMQSPNZ-UHFFFAOYSA-N 1-methylpiperidin-2-amine Chemical class CN1CCCCC1N KJWNKJWHMQSPNZ-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente invención se refiere a un compuesto representado por la siguiente Fórmula Química 1, o a una sal farmacéuticamente aceptable del mismo, y el compuesto según la presente invención puede usarse de manera útil para la prevención o el tratamiento de enfermedades que están asociadas con acciones inhibidoras de quinasas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170183062A KR102577242B1 (ko) | 2017-12-28 | 2017-12-28 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP20035588A true ECSP20035588A (es) | 2020-07-31 |
Family
ID=67067897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202035588A ECSP20035588A (es) | 2017-12-28 | 2020-06-29 | Derivado de amino-metil piperidina como inhibidor de quinasa |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11407754B2 (es) |
| EP (1) | EP3733674B1 (es) |
| JP (1) | JP7024091B2 (es) |
| KR (1) | KR102577242B1 (es) |
| CN (1) | CN111527088B (es) |
| AU (1) | AU2018394996B2 (es) |
| BR (1) | BR112020013237A2 (es) |
| CA (1) | CA3085160C (es) |
| CL (1) | CL2020001749A1 (es) |
| CO (1) | CO2020007156A2 (es) |
| DO (1) | DOP2020000111A (es) |
| EC (1) | ECSP20035588A (es) |
| ES (1) | ES2924225T3 (es) |
| MA (1) | MA51433A (es) |
| MX (1) | MX2020006798A (es) |
| MY (1) | MY196572A (es) |
| PE (1) | PE20210549A1 (es) |
| PH (1) | PH12020550993A1 (es) |
| RU (1) | RU2756505C1 (es) |
| SA (1) | SA520412334B1 (es) |
| SG (1) | SG11202004916YA (es) |
| TN (1) | TN2020000081A1 (es) |
| WO (1) | WO2019132561A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10392368B2 (en) | 2017-08-01 | 2019-08-27 | Theravance Biopharma R&D Ip, Llc | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors |
| CA3084962C (en) | 2017-12-28 | 2022-08-09 | Daewoong Pharmaceutical Co., Ltd. | Oxy-fluoropiperidine derivatives as kinase inhibitor |
| KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
| CA3125039A1 (en) | 2019-01-23 | 2020-07-30 | Theravance Biopharma R&D Ip, Llc | Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors |
| KR102228668B1 (ko) * | 2019-10-08 | 2021-03-17 | (주)부흥산업사 | 메틸피퍼리딘 아미노피롤로 피리미딘의 제조방법 |
| CN112824381B (zh) * | 2019-11-21 | 2024-04-26 | 广东东阳光药业股份有限公司 | 一种哌啶胺的制备方法 |
| US11697648B2 (en) | 2019-11-26 | 2023-07-11 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as JAK inhibitors |
| CN115023428B (zh) * | 2020-01-21 | 2025-04-08 | 江苏先声药业有限公司 | 嘧啶并吡咯类化合物 |
| WO2021147953A1 (zh) * | 2020-01-21 | 2021-07-29 | 江苏先声药业有限公司 | 嘧啶并五元环类衍生物及其应用 |
| CN113214265B (zh) * | 2020-01-21 | 2023-07-07 | 江苏先声药业有限公司 | 嘧啶并五元环类化合物 |
| TW202214643A (zh) * | 2020-09-22 | 2022-04-16 | 大陸商江蘇先聲藥業有限公司 | 嘧啶并吡咯類化合物 |
| CN114315838B (zh) * | 2020-09-30 | 2024-09-03 | 江苏先声药业有限公司 | 嘧啶并吡咯类化合物 |
| WO2023165562A1 (zh) * | 2022-03-02 | 2023-09-07 | 南京明德新药研发有限公司 | 含氮杂环类化合物及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| CN105362277A (zh) | 2008-07-16 | 2016-03-02 | 药品循环有限公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
| JP5918693B2 (ja) | 2009-05-05 | 2016-05-18 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Ｅｇｆｒ阻害剤及び疾患の治療方法 |
| MX342164B (es) | 2010-06-23 | 2016-09-19 | Hanmi Science Co Ltd | Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa. |
| MD20140023A2 (ro) | 2011-09-22 | 2014-06-30 | Pfizer Inc. | Derivaţi de pirolpirimidină şi purină |
| DK2880035T3 (en) | 2012-08-06 | 2017-03-06 | Acea Biosciences Inc | Hitherto UNKNOWN PYRROLOPYRIMIDINE COMPOUNDS AS PROTEIN CHINAS INHIBITORS |
| TR201904813T4 (tr) | 2012-11-08 | 2019-04-22 | Compac Tech Limited | Bir derecelendirme aparatı için ürün taşıyıcısı. |
| US9346812B2 (en) | 2013-01-16 | 2016-05-24 | Signal Pharmaceuticals, Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| US9840517B2 (en) * | 2013-09-18 | 2017-12-12 | Beijing Hanmi Pharmaceutical Co., Ltd. | Compound inhibiting activities of BTK and/or JAK3 kinases |
| WO2015083028A1 (en) | 2013-12-05 | 2015-06-11 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
| CN105732637B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| CN108934162A (zh) | 2015-12-16 | 2018-12-04 | 南方研究所 | 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法 |
| CN113135920A (zh) | 2016-06-30 | 2021-07-20 | 株式会社大熊制药 | 吡唑并嘧啶衍生物作为激酶抑制剂 |
| CN106432294B (zh) | 2016-09-19 | 2018-01-30 | 淮北师范大学 | 发光配合物及其制备方法 |
| KR102032418B1 (ko) | 2017-06-15 | 2019-10-16 | 한국화학연구원 | 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| KR102577241B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체 |
| KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
| CA3084962C (en) | 2017-12-28 | 2022-08-09 | Daewoong Pharmaceutical Co., Ltd. | Oxy-fluoropiperidine derivatives as kinase inhibitor |
-
2017
- 2017-12-28 KR KR1020170183062A patent/KR102577242B1/ko active Active
-
2018
- 2018-12-28 MX MX2020006798A patent/MX2020006798A/es unknown
- 2018-12-28 MA MA051433A patent/MA51433A/fr unknown
- 2018-12-28 EP EP18897615.3A patent/EP3733674B1/en active Active
- 2018-12-28 SG SG11202004916YA patent/SG11202004916YA/en unknown
- 2018-12-28 BR BR112020013237-3A patent/BR112020013237A2/pt unknown
- 2018-12-28 CA CA3085160A patent/CA3085160C/en active Active
- 2018-12-28 MY MYPI2020002466A patent/MY196572A/en unknown
- 2018-12-28 PH PH1/2020/550993A patent/PH12020550993A1/en unknown
- 2018-12-28 AU AU2018394996A patent/AU2018394996B2/en active Active
- 2018-12-28 WO PCT/KR2018/016813 patent/WO2019132561A1/ko not_active Ceased
- 2018-12-28 TN TNP/2020/000081A patent/TN2020000081A1/en unknown
- 2018-12-28 CN CN201880083535.6A patent/CN111527088B/zh active Active
- 2018-12-28 US US16/770,213 patent/US11407754B2/en active Active
- 2018-12-28 RU RU2020124575A patent/RU2756505C1/ru active
- 2018-12-28 ES ES18897615T patent/ES2924225T3/es active Active
- 2018-12-28 JP JP2020534937A patent/JP7024091B2/ja active Active
- 2018-12-28 PE PE2020000794A patent/PE20210549A1/es unknown
-
2020
- 2020-06-10 DO DO2020000111A patent/DOP2020000111A/es unknown
- 2020-06-11 CO CONC2020/0007156A patent/CO2020007156A2/es unknown
- 2020-06-25 SA SA520412334A patent/SA520412334B1/ar unknown
- 2020-06-26 CL CL2020001749A patent/CL2020001749A1/es unknown
- 2020-06-29 EC ECSENADI202035588A patent/ECSP20035588A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020001754A1 (es) | Derivado de amino-fluoropiperidina como inhibidor de quinasa. | |
| ECSP20035588A (es) | Derivado de amino-metil piperidina como inhibidor de quinasa | |
| DOP2020000112A (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
| ECSP18093777A (es) | Derivados de pirazolopirimidina como inhibidor de quinasa | |
| CO2019004034A2 (es) | Compuesto de piridina | |
| ECSP17029203A (es) | Inhibidor de cinasa aurora a | |
| CU20160111A7 (es) | Compuestos de heterociclilo bicíclico como inhibidores de irak4 | |
| PE20151654A1 (es) | Inhibidores de cdc7 | |
| DOP2019000194A (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
| MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. |